Vanessa Peruhype-Magalhães

ORCID: 0000-0002-2907-2724
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Research on Leishmaniasis Studies
  • Trypanosoma species research and implications
  • Mosquito-borne diseases and control
  • SARS-CoV-2 and COVID-19 Research
  • Viral Infections and Vectors
  • Immune Cell Function and Interaction
  • T-cell and Retrovirus Studies
  • T-cell and B-cell Immunology
  • Viral Infections and Outbreaks Research
  • Parasites and Host Interactions
  • Animal Disease Management and Epidemiology
  • vaccines and immunoinformatics approaches
  • COVID-19 Clinical Research Studies
  • Systemic Lupus Erythematosus Research
  • Immunotherapy and Immune Responses
  • Immunodeficiency and Autoimmune Disorders
  • Autoimmune and Inflammatory Disorders Research
  • Rheumatoid Arthritis Research and Therapies
  • Respiratory viral infections research
  • Eosinophilic Disorders and Syndromes
  • Immune Response and Inflammation
  • Reproductive System and Pregnancy
  • Immune responses and vaccinations
  • Leprosy Research and Treatment
  • Neuroinflammation and Neurodegeneration Mechanisms

Fundação Oswaldo Cruz
2016-2025

Universidade Federal do Espírito Santo
2022

Universidade Federal de Goiás
2022

Universidade Federal de Minas Gerais
2022

Universidade Federal Fluminense
2022

Universidade Federal do Amazonas
2022

Universidade Federal de Juiz de Fora
2022

Universidade Federal da Paraíba
2022

Hospital Geral de Fortaleza
2022

Universidade Federal do Rio Grande do Sul
2022

Summary Considering the complexity of immunological events triggered during active visceral Leishmaniasis (VL), relevance segregation immune response human VL into type 1 and 2 still remains unclear. For this purpose, in individuals living risk areas for VL, we have evaluated especially asymptomatic patients with plasmatic levels cytokines reactive nitrogen species under ex vivo conditions. In addition, also performed an analysis intracellular cytokine patterns circulating leucocytes after...

10.1111/j.1365-2249.2006.03171.x article EN Clinical & Experimental Immunology 2006-08-08

The live attenuated 17DD Yellow Fever vaccine is one of the most successful prophylactic interventions for controlling disease expansion ever designed and utilized in larger scale. However, increase on worldwide demands manufacturing restrictions urge more detailed dose sparing studies. establishment complementary biomarkers addition to PRNT Viremia could support a secure decision-making regarding use YF subdoses. present work aimed at comparing serum chemokine cytokine kinetics triggered by...

10.1186/1471-2334-14-391 article EN cc-by BMC Infectious Diseases 2014-07-15

Abstract We investigated the cytokine profile of cells innate immune response and its association with active (ACT), asymptomatic (AS) cured (CUR) human visceral leishmaniasis (VL), as well noninfected (NI) subjects. The frequency cytokine‐producing was determined after short‐term in vitro incubation whole peripheral blood samples soluble Leishmania antigen (SLA). Our data demonstrated a predominant type 2 NI ACT. In NI, we observed an increase IL‐4 + neutrophils, IL‐10 eosinophils besides...

10.1111/j.1365-3083.2005.01686.x article EN Scandinavian Journal of Immunology 2005-11-01

A single vaccination of Yellow Fever vaccines is believed to confer life-long protection. In this study, results vaccinees who received a dose 17DD-YF immunization followed over 10 y challenge premise. YF-neutralizing antibodies, subsets memory T and B cells as well cytokine-producing lymphocytes were evaluated in groups adults before (NVday0) after (PVday30-45, PVyear1-4, PVyear5-9, PVyear10-11, PVyear12-13) primary vaccination. antibodies decrease significantly from PVyear1-4 PVyear12-13...

10.1080/21645515.2015.1082693 article EN cc-by-nc Human Vaccines & Immunotherapeutics 2015-09-11

Massive vaccination positively impacted the SARS-CoV-2 pandemic, being a strategy to increase titers of neutralizing antibodies (NAbs) in population. Assessing NAb levels and understanding kinetics responses is critical for evaluating immune protection. In this study, we optimized validated PRNT50 assay assess 50% virus neutralization evaluated its accuracy measure NAbs original strain or variant SARS-CoV-2. The optimal settings were selected, such as cell (2 × 105 cells/well) CMC (1.5%)...

10.3390/diseases12010029 article EN cc-by Diseases 2024-01-18

The present study aimed to evaluate the performance of plasma immune mediators in classifying leprosy patients [L(PB) and L(MB), paucibacillary multibacillary leprosy, respectively], reaction (T1LR T2LR, type 1 2 reaction, respectively), household contacts (HHC), non-infected (NI) controls. Quantitative measurements these were carried out using high-throughput multiplex microbead array. results demonstrated that most increased all clinical groups compared with NI Higher frequencies but lower...

10.3389/fimmu.2025.1513060 article EN cc-by Frontiers in Immunology 2025-03-05

Peripheral blood samples of 138 co-habitants from 25 families with recently diagnosed cases visceral leishmaniasis in the Metropolitan Region Belo Horizonte, Minas Gerais, Brazil, were analyzed by indirect fluorescent antibody test (IFAT), rK39 and Leishmania chagasi Enzyme Linked Immunosorbent Assay (ELISA), intradermal skin-test Polymerase Chain Reaction (PCR) over a 12-month period. The cumulative positivity was significantly higher PCR (29.7%) than IFAT, ELISA, L. ELISA (5.1%, 6.5%,...

10.1016/j.trstmh.2008.02.007 article EN Transactions of the Royal Society of Tropical Medicine and Hygiene 2008-03-26

ABSTRACT Yellow fever (YF) vaccines (17D-204 and 17DD) are well tolerated cause very low rates of severe adverse events (YEL-SAE), such as serious allergic reactions, neurotropic diseases (YEL-AND), viscerotropic (YEL-AVD). Viral host factors have been postulated to explain the basis YEL-SAE. However, mechanisms underlying occurrence YEL-SAE remain unknown. The present report provides a detailed immunological analysis 23-year-old female patient. patient developed suspected case YEL-AVD with...

10.1128/cvi.00369-09 article EN Clinical and Vaccine Immunology 2009-11-12

Over past decades the 17DD yellow fever vaccine has proved to be effective in controlling and promises a vector for other diseases, but cellular molecular mechanisms by which it elicits such broad-based immunity are still unclear. In this study we describe detailed phenotypic investigation of major minor peripheral blood lymphocyte subpopulations aimed at characterizing kinetics adaptive immune response following primary vaccination. Our finding is decreased frequency circulating CD19+ cells...

10.1111/j.1365-2249.2006.03317.x article EN Clinical & Experimental Immunology 2007-02-07

Immunological alterations associated with aging (immunosenescence) do not represent a simple unidirectional decline in all functions but develop as complex remodeling of the immune system, involving multiple reorganization and developmentally regulated changes. In general, most data available about were obtained at particular age intervals them come from Caucasian individuals either Europe or United States. Here, we report frequencies major lymphocyte subsets healthy Brazilian 2 distinct...

10.1159/000156478 article EN NeuroImmunoModulation 2008-01-01

Abstract In the present study we have evaluated performance of several immunological biomarkers for early diagnosis and prognosis congenital toxoplasmosis. Our results showed that ex vivo serum levels CXCL9, frequencies circulating CD4 + CD25 T-cells T. gondii -specific IFN-γ measured 30–45 days after birth presented high accuracy to distinguish -infected infants from healthy age-matched controls (Global Accuracy/AUC = 0.9; 0.9 0.8, respectively). Of note was enhanced (Accuracy 96%) achieved...

10.1038/s41598-020-73265-z article EN cc-by Scientific Reports 2020-10-07

Yellow Fever (YF) vaccination is suggested to induce a large number of adverse events (AE) and suboptimal responses in patients with autoimmune diseases (AID); however, there have been no studies on 17DD-YF primary performance AID. This prospective non-interventional study conducted between March July, 2017 assessed the safety immunogenicity planned Adult AID (both sexes) were enrolled, along healthy controls (HC), at single hospital (Vitória, Brazil). Included referred for by...

10.3389/fimmu.2020.01382 article EN cc-by Frontiers in Immunology 2020-07-17

The performances of two rapid tests and a standard serological test for the diagnosis visceral leishmaniasis (VL) were compared using sera from 193 patients with VL 85 controls. Kala-Azar Detect®, IT-LEISH® IFI-LH® assays showed sensitivities 88.1%, 93.3% 88.6%, respectively, specificities 90.6%, 96.5% 80%, respectively. sensitivity values similar both tests, but specificity positive predictive higher than corresponding IFI-LH®. Both satisfactory can be used in primary health care settings;...

10.1590/s0074-02762012000700019 article EN cc-by Memórias do Instituto Oswaldo Cruz 2012-11-01

This study aimed at establishing the immunological signature and an algorithm for clinical management of different stages HTLV-1-infection based on serum biomarkers. A panel biomarkers was evaluated by four sets innovative/non-conventional data analysis approaches in samples from 87 HTLV-1 patients: asymptomatic carriers (AC), putative associated myelopathy/tropical spastic paraparesis (pHAM/TSP) HAM/TSP. The cumulative curves molecular signatures pointed out that HAM/TSP presented a...

10.3109/1354750x.2015.1094141 article EN Biomarkers 2015-10-03

Abstract The re-emergence of yellow fever (YF) urged new mass vaccination campaigns and, in 2017, the World Health Organization approved use fractional dose (FD) YF vaccine due to stock shortage. In an observational cross-sectional investigation, we have assessed viremia, antibodies, soluble mediators and effector memory T B-cells induced by primary volunteers with FD standard (SD). Similar viremia levels antibodies markers were early after immunization. However, a faster decrease latter was...

10.1038/s41541-024-00836-w article EN cc-by npj Vaccines 2024-03-08
Coming Soon ...